Immune checkpoint blockade response in mucinous tubular and spindle cell carcinoma Journal Article

   


Authors: Makker, S.; Shah, N. J.; Carlo, M. I.; Kuo, F.; Hakimi, A. A.; Chen, Y. B.; Iyer, G.; Kotecha, R. R.
Article Title: Immune checkpoint blockade response in mucinous tubular and spindle cell carcinoma
Abstract: Mucinous tubular and spindle cell carcinoma (MTSCC) is a rare kidney tumor which is usually characterized by indolent disease physiology. While several high-grade and sarcomatoid MTSCC tumors have been reported, the clinical experience with contemporary immune checkpoint blockade (ICB) combination therapies extrapolated from treatment paradigms of conventional renal cell carcinoma (RCC) remains limited. Here, we report two patients with metastatic MTSCC treated with first-line ipilimumab plus nivolumab therapy who both achieved great clinical benefit. We subsequently performed immune deconvolution analysis on previously identified MTSCC-like kidney tumors from The Cancer Genome Atlas (TCGA) and discovered significantly higher PD-L1 transcriptomic expression compared to similar papillary RCC tumors, providing additional biomarker data supporting the observed ICB response. These data implicate ICB therapy as an effective treatment for patients with metastatic MTSCC. © 2025 by the authors.
Keywords: immunohistochemistry; clinical article; human tissue; protein expression; aged; middle aged; gene mutation; case report; hepatitis; drug withdrawal; nuclear magnetic resonance imaging; cancer grading; ipilimumab; computer assisted tomography; multiple cycle treatment; epidermal growth factor receptor; adenocarcinoma, mucinous; creatinine; hemoglobin; pathology; renal cell carcinoma; kidney neoplasms; nephrectomy; protein tyrosine kinase inhibitor; rash; radical nephrectomy; kidney tumor; carcinoma, renal cell; angiomyolipoma; heterozygosity; methylprednisolone; hypothyroidism; levothyroxine; drug therapy; cryoablation; 2 methylacyl coenzyme a racemase; colloid carcinoma; carcinomatosis; pd-1; programmed death 1 ligand 1; programmed death 1 receptor; mucinous tubular and spindle cell carcinoma; lymphocyte activation gene 3 protein; transcription factor pax8; immune checkpoint inhibitor; nivolumab; lenvatinib; humans; human; male; female; article; pembrolizumab; immune checkpoint inhibitors; positron emission tomography-computed tomography; mutl protein homolog 1; mtscc; checkpoint inhibitor therapy
Journal Title: Current Oncology
Volume: 32
Issue: 2
ISSN: 1198-0052
Publisher: Multimed Inc  
Date Published: 2025-02-01
Start Page: 94
Language: English
DOI: 10.3390/curroncol32020094
PUBMED: 39996894
PROVIDER: scopus
PMCID: PMC11854795
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85218680138&doi=10.3390%2fcurroncol32020094&partnerID=40&md5=fef44606d55465924774cac4ea052f31
Notes: Article -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PubMed and PDF -- MSK corresponding author is Ritesh Kotecha -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Gopakumar Vasudeva Iyer
    342 Iyer
  2. Yingbei Chen
    393 Chen
  3. Abraham Ari Hakimi
    323 Hakimi
  4. Maria Isabel Carlo
    161 Carlo
  5. Fengshen Kuo
    80 Kuo
  6. Ritesh Rajesh Kotecha
    91 Kotecha
  7. Neil Jayendra Shah
    83 Shah
Related MSK Work